Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Achillion Pharmaceuticals

Related ACHN
Deutsche Bank Loves These Small-Cap Biotech Stocks
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

In a report published Friday, Piper Jaffray & Co. reiterated its Overweight rating on Achillion Pharmaceuticals (NASDAQ: ACHN), but slightly lowered its price target from $17.00 to $16.00.

Piper Jaffray noted, “Achillion ended 2Q:12 with cash of $60 million and received gross proceeds of $41.8 million by issuing QVT 6.367 million shares at $6.57. Achillion has begun dosing HCV genotype 1 patients with NS5A inhibitor ACH-3102 with data in 3Q:12. We expect Achillion to begin Phase II combo trials with protease inhibitor sovaprevir by year-end with data in early 2013. Recent set-backs with Bristol-Myers' and Idenix's ‘nucs' benefit Achillion. We expect the wave of consolidation in HCV will continue with Achillion a likely target. We reiterate our Overweight rating and are trimming our target to $16 from $17 to account for dilution from the QVT deal.”

Achillion Pharmaceuticals closed on Thursday at $6.57.

Latest Ratings for ACHN

Dec 2014BairdDowngradesOutperformNeutral
Dec 2014Deutsche BankMaintainsBuy
Sep 2014UBSMaintainsBuy

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings


Related Articles (ACHN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional